Peptomyc is a clinical-stage biotechnology company headquartered in Barcelona, Spain, specializing in the development of protein and peptide therapeutics for cancer.
Subscribe to see Peptomyc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Peptomyc is a drug discovery company headquartered in Barcelona, Spain. Its most recent funding round, Seed, closed in February 2026. Xcout tracks 2 named people at Peptomyc, including Laura Soucek (CEO and co-founder).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Peptomyc's closest competitors — see the full list of competitors and alternatives →
Ona Therapeutics is a biotechnology company founded in 2019 and headquartered in Barcelona, Spain, specializing in the design of first-in-class biotherapeutics and ADCs to attack advanced cancer.
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
Promontory Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company founded in 2010 and headquartered in New York, NY. The firm focuses on small molecule immunotherapy.
Momotaro-Gene Inc. is a drug discovery company established in 2007 and headquartered in Okayama, Japan. The company focuses on pharmaceutical research and the development of next-generation cancer therapeutics.
Albatroz Therapeutics is a pre-clinical stage biotechnology company based in Singapore that is developing first-in-class antibody therapeutics to protect the extracellular matrix and treat solid tumors.
PAQ Therapeutics is a clinical-stage biotechnology company that utilizes autophagy to develop small-molecule KRAS degraders for the treatment of lethal cancers. The company's research focuses on restoring health and curing diseases that currently lack effective treatment options.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Peptomyc? Suggest a correction · Work at Peptomyc? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.